T. Rowe Price Associates’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-24,747
| Closed | -$481K | – | 2633 |
|
|
2018
Q1 | $481K | Buy |
24,747
+143
| +0.6% | +$2.81K | ﹤0.01% | 2105 |
|
|
2017
Q4 | $410K | Hold |
24,604
| – | – | ﹤0.01% | 2168 |
|
|
2017
Q3 | $499K | Sell |
24,604
-8,300
| -25% | -$159K | ﹤0.01% | 2099 |
|
|
2017
Q2 | $530K | Sell |
32,904
-4,130
| -11% | -$61K | ﹤0.01% | 2044 |
|
|
2017
Q1 | $468K | Buy |
37,034
+12,764
| +53% | +$154K | ﹤0.01% | 2091 |
|
|
2016
Q4 | $322K | Buy |
24,270
+420
| +2% | +$7.18K | ﹤0.01% | 2230 |
|
|
2016
Q3 | $565K | Buy |
23,850
+3,810
| +19% | +$102K | ﹤0.01% | 1962 |
|
|
2016
Q2 | $578K | Hold |
20,040
| – | – | ﹤0.01% | 1906 |
|
|
2016
Q1 | $642K | Buy |
20,040
+460
| +2% | +$16.2K | ﹤0.01% | 1870 |
|
|
2015
Q4 | $837K | Buy |
19,580
+1,680
| +9% | +$67.1K | ﹤0.01% | 1750 |
|
|
2015
Q3 | $630K | Hold |
17,900
| – | – | ﹤0.01% | 1851 |
|
|
2015
Q2 | $822K | Buy |
17,900
+1,900
| +12% | +$90.2K | ﹤0.01% | 1812 |
|
|
2015
Q1 | $750K | Sell |
16,000
-2,300
| -13% | -$91.5K | ﹤0.01% | 1826 |
|
|
2014
Q4 | $580K | Hold |
18,300
| – | – | ﹤0.01% | 1905 |
|
|
2014
Q3 | $434K | Hold |
18,300
| – | – | ﹤0.01% | 2000 |
|
|
2014
Q2 | $549K | Hold |
18,300
| – | – | ﹤0.01% | 1908 |
|
|
2014
Q1 | $483K | Buy |
18,300
+3,800
| +26% | +$95K | ﹤0.01% | 1932 |
|
|
2013
Q4 | $365K | Sell |
14,500
-3,100
| -18% | -$69.2K | ﹤0.01% | 2050 |
|
|
2013
Q3 | $361K | Hold |
17,600
| – | – | ﹤0.01% | 2020 |
|
|
2013
Q2 | $351K | Buy |
+17,600
| New | +$312K | ﹤0.01% | 2007 |
|
T. Rowe Price Associates's IPXL Position: Q2 2018 in Review
T. Rowe Price Associates sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 24,747 shares — an estimated $481K sold.
T. Rowe Price Associates first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $837K in Q4 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- T. Rowe Price Associates reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- T. Rowe Price Associates sold 24,747 Impax Laboratories, Inc. shares in Q2 2018, an estimated $481K.
- T. Rowe Price Associates first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- T. Rowe Price Associates's Impax Laboratories, Inc. position peaked at $837K in Q4 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on T. Rowe Price Associates's 13F filing for Q2 2018, filed 14 Aug 2018.